Cambridge biotechnology company Bind Therapeutics Inc., which is developing a class of programmable drugs to fight lung cancer, prostate cancer, and other diseases, registered Monday for an initial public offering to raise up to $80.5 million.
Bind becomes the eighth Massachusetts biotech to file an IPO registration statement in 2013. Five state biotech start-ups had gone public through the end of July, and Foundation Medicine of Cambridge, a supplier of genomic testing for cancer patients, filed plans to raise $86.2 million. Last week, Acceleron Pharma Inc. of Cambridge, which is developing treatments for rare blood disorders, registered for an IPO that could raise $74.8 million.
In its filing with the Securities and Exchange Commission, the company said it had already raised $94.7 million to fund its operations and accumulated a deficit of $82.5 million through March 31. The company filed to be listed on the Nasdaq stock exchange with the ticker BIND.
Robert Weisman can be reached at firstname.lastname@example.org. Follow him on Twitter @GlobeRobW.